๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity โ—† Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing โ—† Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich โ—† Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery โ—† Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma โ—† Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity โ—† Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing โ—† Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich โ—† Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery โ—† Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma โ—† Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—†
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Heidelberg
Clinical trial register · Australia

Clinical Trials in Heidelberg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 3335 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
3335
Studies in scope
all four open statuses
1809
Recruiting now
open to new participants
761
Lead sponsors
across recruiting studies
Top sites
Melbourne 1088 Adelaide 564 Sydney 509 Westmead 414 Clayton 408
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca27 Janssen Research & Development, LLC16 AbbVie12 Hoffmann-La Roche11 Bristol-Myers Squibb10
Site location
Melbourne1088 Adelaide564 Sydney509 Westmead414 Clayton408
All 398 locations
Target enrolment
to

Trials with a site in Heidelberg

263 of 3335 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Not yet open
Speed of Lung Inflation During Ventilation of Extremely Preterm Infants
NCT07101419Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant
Murdoch Childrens Research Institute
Not applicable
68
Heidelberg, Parkville, Saint Albans
2027-02
Not yet open
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
NCT07739017Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma
Olivia Newton-John Cancer Research Institute
Phase 1
54
Herston, Heidelberg
2026-12
Not yet open
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
NCT07634289Relapsed /Refractory DLBCL
DrugsGlofitamab·Obinutuzumab
Olivia Newton-John Cancer Research Institute
Phase 2
40
Douglas, Woolloongabba, Bedford Park, Heidelberg, Murdoch
2026-12
Not yet open
A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)
NCT07827144Solid Tumours
AIMEDBIO
Phase 1
90
Heidelberg
2026-09-30
Not yet open
Exploration of Current and New Technologies for Accuracy of Diagnosing OSA
NCT07485582Obstructive Sleep Apnea
ResMed
Observational
90
Adelaide, Woodville South, Perth, Heidelberg
2026-09
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsImzokitug·Vedolizumab·Infliximab·Pumitamig
Bristol-Myers Squibb
Phase 2
160
Gosford, Westmead, Greenslopes, Heidelberg, Perth
2026-08-31
Recruiting
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
NCT07742735Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
DrugApraglutide
VectivBio AG
Phase 3
124
Fitzroy, Heidelberg, Herston, Perth
2026-08
Recruiting
Feasibility Study of the iVEAcare Neuromodulation System for the Treatment of Drug-Resistant Epilepsy
NCT07640191Drug Resistant Epilepsy
iVEAcare
Not applicable
30
Herston, South Brisbane, Clayton, Fitzroy, Heidelberg, Melbourne, Parkville
2026-07-29
Recruiting
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
NCT07287202Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC), Hemimegalencephaly
DrugPaxalisib
Sovargen
Phase 1/2
12
Heidelberg, Melbourne
2026-07-14
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
NCT07619287Myeloid Malignancy
DrugBG-75202
BeOne Medicines
Phase 1
118
Concord, Kogarah, Kurralta Park, Geelong, Heidelberg, Nedlands
2026-06-23
Not yet open
A Phase III Randomised Clinical Trial of Ultrasound Groin Monitoring Versus Groin Lymph Node Dissection to De-Escalate the Extent of Surgery in Vulvar Cancer
NCT06476639Vulvar Cancer Stage I, Vulvar Cancer Stage II, Lymph Node Metastasis, Groin Node
Queensland Centre for Gynaecological Cancer
Phase 3
640
Newcastle, Darwin, Auchenflower, Brisbane, Buderim, Adelaide, Heidelberg, Parkville
2026-06-01
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
700
Darlinghurst, Garran, Heidelberg, Macquarie University, Melbourne, Perth, Port Macquarie
2026-05-31
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT07422480Myelodysplastic Syndrome, Anemia
DrugsElritercept·Epoetin Alfa
Takeda
Phase 3
300
Coffs Harbour, Sydney, Waratah, Adelaide, Bedford Park, Clayton, Fitzroy, Heidelberg
2026-05-21
Recruiting
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
NCT07509151Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
DrugSurovatamig
AstraZeneca
Phase 3
420
Adelaide, Fitzroy, Heidelberg, Nedlands, Perth, Rockingham
2026-05-05
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
NCT07567846Advanced Prostate Cancer, Metastatic Prostate Cancer
Genentech, Inc.
Phase 1/2
260
Darlinghurst, Heidelberg
2026-04-29
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
DrugBI 3000202
Boehringer Ingelheim
Phase 2
405
Heidelberg, Murdoch
2026-04-20
Recruiting
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT07287670Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics
Phase 2
85
Southport, Woolloongabba, Heidelberg
2026-04-16
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351Advanced Renal Cell Carcinoma (RCC)
DrugsCasdatifan·Pumitamig·Cabozantinib·Ipilimumab
Bristol-Myers Squibb
Phase 1/2
474
North Ryde, St Leonards, Brisbane, Herston, Heidelberg, Malvern
2026-03-26
Recruiting
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
NCT07197580ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
40
Sydney, Wollongong, Heidelberg, Melbourne N., Murdoch
2026-03-25
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 3
1,600
Blacktown, Camperdown, Meadowbrook, Oaklands Park, Heidelberg, Melbourne
2026-03-23
Recruiting
Study in Advanced Solid Tumor Patients
NCT07300943Advanced Solid Tumor
Callio Therapeutics
Phase 1/2
306
Randwick, South Brisbane, Box Hill, Heidelberg, Melbourne, Nedlands
2026-03-19
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Blacktown, St Leonards, Oaklands Park, Heidelberg, Melbourne
2026-03-16
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 2
360
Camperdown, Kogarah, New Lambton Heights, Box Hill, Heidelberg
2026-03-10
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin
AstraZeneca
Phase 3
2,130
Darlinghurst, Garran, Heidelberg, Murdoch, Randwick, Westmead, Woolloongabba
2026-02-03
Not yet open
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin
NCT07225465Type 1 Diabetes Mellitus
DrugDapagliflozin
St Vincent's Hospital Melbourne
Phase 2
115
Fitzroy, Heidelberg, Melbourne, Parkville
2026-02
Recruiting
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT07435038Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
120
Blacktown, Randwick, Sydney, Bedford Park, Heidelberg, Nedlands
2026-01-29
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
DrugsSonrotoclax·Venclyxto·Acalabrutinib·Venclexta
BeOne Medicines
Phase 3
500
Blacktown, Concord, St Leonards, Woolloongabba, Clayton, Heidelberg, Malvern, Melbourne
2026-01-22
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab
Boehringer Ingelheim
Phase 3
400
Bedford Park, Subiaco, Heidelberg, Sydney, Woolloongabba
2026-01-16
Recruiting
Vorasidenib Maintenance for IDH Mutant Astrocytoma
NCT06809322IDH-mutant Grade 2 or 3 Astrocytoma
DrugVorasidenib
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
468
Bedford Park, Camperdown, Heidelberg, Hobart, Liverpool, Melbourne, Nedlands, St Leonards
2026-01-16
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
NCT07284459Idiopathic Pulmonary Fibrosis
Contineum Therapeutics
Phase 2
324
Camperdown, Westmead, Chermside, Greenslopes, Heidelberg, Melbourne, Midland, Spearwood
2026-01-08
Recruiting
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562Multiple Myeloma
DrugsLinvoseltamab·Daratumumab·Lenalidomide·Dexamethasone
European Myeloma Network B.V.
Phase 3
1,000
Adelaide, Box Hill, Canberra, Geelong, Heidelberg, Kingswood, Melbourne, Sunshine Coast
2025-12-23
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
DrugsPasritamig·Prednisone/Prednisolone·Docetaxel
Janssen Research & Development, LLC
Phase 3
800
Heidelberg, Kurralta Park, Melbourne, Wahroonga, Woolloongabba
2025-12-19
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
DrugFurmonertinib
ArriVent BioPharma, Inc.
Phase 3
480
Blacktown, Camperdown, St Leonards, Heidelberg
2025-12-17
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Box Hill, Brisbane, Campbelltown, Heidelberg, Macquarie University, Perth, Randwick, St Albans
2025-12-12
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
DrugBG-75202
BeOne Medicines
Phase 1
86
Blacktown, Camperdown, Adelaide, Heidelberg, Melbourne
2025-12-11
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
DrugRina-S
Genmab
Phase 3
660
Heidelberg, Campbelltown, Camperdown, Waratah, Joondalup
2025-11-28
Recruiting
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.
Phase 2
75
Clayton, Heidelberg, Nedlands, Wollongong
2025-11-26
Recruiting
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
NCT07186842Advanced Solid Cancers
BioNTech SE
Phase 1/2
245
Clayton, Heidelberg
2025-11-18
Active, closed
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,060
Camperdown, Kogarah, Macquarie Park, Bedford Park, Woodville, Box Hill, Heidelberg, Melbourne
2025-11-12
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Kogarah, New Lambton Heights, Westmead, Clayton, Heidelberg, Murdoch, Southport
2025-11-11
Recruiting
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
NCT07064122Haematologic Neoplasms
AstraZeneca
Phase 1
72
Heidelberg, Melbourne
2025-11-03
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Sydney, Waratah, South Brisbane, Adelaide, Clayton, Geelong, Heidelberg, Nedlands
2025-11-03
Recruiting
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
NCT07244705Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC), Immunotherapy
DrugsAvastin·Tislelizumab·Bevacizumab
Anbogen Therapeutics, Inc.
Phase 1/2
66
Liverpool, Macquarie Park, Randwick, Greenslopes, Woodville South, Clayton, Heidelberg, Nedlands
2025-11
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Darlinghurst, Liverpool, Waratah, Birtinya, Hobart, Clayton, Heidelberg, Melbourne
2025-10-24
Recruiting
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
NCT07221227Non-alcoholic Fatty Liver Disease
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
1,200
Broadmeadow, Heidelberg
2025-10-24
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Adelaide, Box Hill, Brisbane, Broadmeadow, Geelong, Heidelberg, Ipswich, Murdoch
2025-10-15
Recruiting
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
NCT07149857Multiple Myeloma
DrugsCilta-cel·Fludarabine·Cyclophosphamide
Janssen Research & Development, LLC
Phase 2
60
Camperdown, Clayton, Heidelberg, Murdoch, Woolloongabba
2025-10-03
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
470
Macquarie University, St Leonards, Heidelberg
2025-09-30
Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312Acute Myeloid Leukemia (AML)
DrugsZiftomenib·Venclyxto·Ara-C·Venclexta
Kura Oncology, Inc.
Phase 3
1,300
Waratah, Heidelberg, Murdoch
2025-09-26
Recruiting
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827Advanced Solid Tumor
DrugsAdrucil·Pembrolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Liverpool, Darlinghurst, Fitzroy, Heidelberg, Nedlands
2025-09-22
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
400
Camperdown, Sydney, Darlinghurst, Chermside, Heidelberg, Murdoch
2025-09-13
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
600
Macquarie University, Brisbane, Ballarat Central, Heidelberg, Melbourne, Subiaco
2025-09-11
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Box Hill, Camperdown, Chermside, Elizabeth Vale, Frankston, Frenchs Forest, Heidelberg, Hobart
2025-09-08
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
DrugsJNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 3
1,203
Heidelberg, Kurralta Park, Melbourne, Murdoch, Woolloongabba
2025-09-02
Recruiting
Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
NCT07055542Allergic Asthma, Thunderstorm Asthma, Seasonal Allergic Rhinitis, Grass Pollen Allergy
University of Melbourne
Not applicable
530
Albury, Box Hill, Clayton, Heidelberg, Melbourne, Parkville
2025-08-27
Recruiting
An International Observational Study of Adults With Acute Infection
NCT07069400Infectious Disease
University of Minnesota
Observational
1,500
Camperdown, Sydney, Westmead, Brisbane, Clayton, Heidelberg, Melbourne, Parkville
2025-08-25
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
DrugsBNT326·Paroxetine·Itraconazole·Pumitamig
BioNTech SE
Phase 1/2
1,438
Blacktown, Darlinghurst, Wollstonecraft, Southport, Adelaide, Frankston, Heidelberg, Melbourne
2025-08-12
Recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516Alzheimer's Disease
DrugVHB937
Novartis Pharmaceuticals
Phase 2
407
Camperdown, Kogarah, Box Hill, Heidelberg, Nedlands
2025-08-07
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Datopotamab deruxtecan
AstraZeneca
Phase 2
278
Heidelberg, Nedlands, Woodville
2025-08-07
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07005102Non-Squamous Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin
AbbVie
Phase 2/3
854
Liverpool, Woodville, Heidelberg, Murdoch
2025-08-03
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502Follicular Lymphoma
DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine
Celgene
Phase 3
400
Westmead, Adelaide, Hobart, Heidelberg, Malvern, Perth
2025-07-28
Recruiting
Young Stroke Service Deep Phenotyping: Exploring Recovery in Young Adult Survivors of Stroke
NCT07019493Stroke Patients, Stroke, Stroke; Sequelae, Young Adults
The Florey Institute of Neuroscience and Mental Health
Observational
100
Heidelberg
2025-07-19
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Westmead, Heidelberg, Melbourne
2025-07-17
Active, closed
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
NCT07010471Developmental and Epileptic Encephalopathy 1
DrugRelutrigine
Praxis Precision Medicines
Phase 3
160
Heidelberg
2025-07-09
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352Alzheimers Disease
Hoffmann-La Roche
Phase 3
80,000
Camperdown, Darlinghurst, Kogarah, Macquarie Park, Bedford Park, Woodville, Box Hill, Heidelberg
2025-07-02
Not yet open
Use of Water Ingestion in Small Intestine Ultrasound
NCT07079007Crohn Disease (CD), Intestine Ultrasonography
Austin Health
Observational
55
Heidelberg
2025-07
Active, closed
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
NCT06987643Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke
DrugNeflamapimod
EIP Pharma Inc
Phase 2
90
Campbelltown, Liverpool, Birtinya, Brisbane, Southport, Box Hill, Heidelberg, Melbourne
2025-06-20
Active, closed
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
NCT07037771Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals
Phase 3
70
Camperdown, Saint Leonards, Heidelberg, Nedlands
2025-06-17
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034Gastrointestinal Neoplasms
DrugRisvutatug Rezetecan
GlaxoSmithKline
Phase 1/2
451
Heidelberg, Melbourne
2025-06-11
Active, closed
REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
NCT06914609Angelman Syndrome
DrugObudanersen
Ionis Pharmaceuticals, Inc.
Phase 3
156
South Brisbane, Heidelberg, Nedlands, Randwick
2025-06-10
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490Multiple Sclerosis Spasticity
DrugIrafamdastat
Celgene
Phase 2
200
Newcastle, Sydney, Kent Town, Box Hill, Heidelberg, Parkville, Nedlands
2025-06-05
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Murdoch, Concord, Heidelberg, Liverpool, Melbourne, South Brisbane, Woolloongabba
2025-05-27
Recruiting
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
NCT06921837Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma
Bolt Biotherapeutics, Inc.
Phase 1/2
122
Darlinghurst, Westmead, Birtinya, Clayton, Heidelberg
2025-05-26
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab
AstraZeneca
Phase 3
150
Chermside, Elizabeth Vale, Heidelberg, Hong Kong, Kogarah, Macquarie University, Murdoch, Port Macquarie
2025-05-15
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab
AstraZeneca
Phase 3
1,220
Auchenflower, Camperdown, Clayton, Heidelberg, Randwick
2025-05-06
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463Metastatic Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Panitumumab·Leucovorin·Fluorouracil
AbbVie
Phase 2
390
Sydney, South Brisbane, Woodville South, Heidelberg, Nedlands
2025-04-24
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Auchenflower, Birtinya, Heidelberg, Kurralta Park, North Tamworth, Perth, Shepparton, Traralgon
2025-03-27
Recruiting
Spinal Cord Injury Neurorecovery Collaboration
NCT06871254Spinal Cord Injuries
University of Melbourne
Not applicable
24
Heidelberg
2025-03-01
Recruiting
A Phase โ…ข Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil
AstraZeneca
Phase 3
840
Darlinghurst, Heidelberg, Murdoch, Westmead
2025-03-01
Active, closed
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323Small Cell Lung Cancer (SCLC)
DrugTarlatamab
Amgen
Phase 2
252
Clayton, Heidelberg
2025-02-26
By invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226Developmental and Epileptic Encephalopathy
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
324
Randwick, Westmead, Brisbane, Heidelberg, Parkville
2025-02-12
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin
BioNTech SE
Phase 3
621
Waratah, Wollongong, Cairns, Kurralta Park, Woodville, Frankston, Heidelberg, St Albans
2025-02-03
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Heidelberg, Melbourne, Nedlands
2025-01-30
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Camperdown, Kingswood, Waratah, Southport, Tugun, Heidelberg, North Melbourne, Murdoch
2025-01-28
Active, closed
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06291220Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsABBV-453·Obinutuzumab
AbbVie
Phase 1
4
Sydney, Southport, Heidelberg, Perth
2025-01-27
Recruiting
Implementing Surgery School Prehabilitation Using Telehealth
NCT06631872Adults Waiting to Undergo Lung Cancer or Major Abdominal, Open or Video Assisted Cancer Surgery
University of Melbourne
Not applicable
515
New Lambton Heights, Waratah, Southport, Woolloongabba, Burnie, Launceston, Heidelberg, Melbourne
2025-01-22
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774Chronic Graft-versus-host-disease
DrugsAxatilimab·Prednisolone·Methylprednisolone·Prednisone
Incyte Corporation
Phase 3
240
Sydney, Adelaide, Heidelberg
2025-01-21
Active, closed
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
NCT06456463Acute Myeloid Leukemia
DrugsTagraxofusp·Azacitidine·Venetoclax
Stemline Therapeutics, Inc.
Phase 2
85
Concord, Douglas, Adelaide, Box Hill, Clayton, Fitzroy, Heidelberg, Perth
2025-01-14
Recruiting
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
NCT06908356Focal Onset Seizure, Primary Generalized Epilepsy
Praxis Precision Medicines
Phase 2
50
Heidelberg, Melbourne
2025-01-10
Recruiting
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
NCT06589596Advanced Solid Tumor
DrugBGB-58067
BeOne Medicines
Phase 1
525
Blacktown, Woolloongabba, Clayton, Heidelberg, Nedlands
2025-01-10
Recruiting
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NCT06706076NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics
Phase 1/2
675
Heidelberg, Melbourne
2025-01-09
Recruiting
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
NCT06613009Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
190
Westmead, Wollongong, Heidelberg
2024-12-30
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Irinotecan·Adrucil
Janssen Research & Development, LLC
Phase 3
700
Concord, Heidelberg, South Woodville, St Albans
2024-12-12
Active, closed
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686Idiopathic Pulmonary Fibrosis (IPF)
Vicore Pharma AB
Phase 2
378
Footscray, Adelaide, Brisbane, Concord, Darlinghurst, Douglas, Heidelberg, Sydney
2024-12-09
Recruiting
BMB-101 in Absence Epilepsy and DEE
NCT06401538Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome, Lennox Gastaut Syndrome
DrugBMB-101
Bright Minds Biosciences Pty Ltd
Phase 2
20
Randwick, Herston, Fitzroy, Heidelberg, Melbourne
2024-12-05
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Heidelberg, Kogarah, Macquarie University, Nedlands
2024-11-27
Recruiting
LIVERAGEโ„ข - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Concord, Kingswood, Liverpool, Westmead, Clayton, Heidelberg, Parkville, Perth
2024-11-12
Active, closed
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141Developmental and Epileptic Encephalopathy
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
367
Randwick, Westmead, Brisbane, Heidelberg, Melbourne, Parkville
2024-11-11
Recruiting
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
NCT06634849Advanced Solid Tumor
Pathios Therapeutics Pty Ltd
Phase 1/2
30
Blacktown, Randwick, Adelaide, Heidelberg, Nedlands
2024-11-04
Recruiting
LIVERAGEโ„ข: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Concord, Kingswood, Liverpool, Westmead, Birtinya, Clayton, Heidelberg, Parkville
2024-10-14
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
DrugsTagrisso·Datopotamab deruxtecan·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
744
Fitzroy, Heidelberg, Kogarah, Liverpool, Nedlands, Port Macquarie, St Leonards, Westmead
2024-10-04
Recruiting
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
NCT06561048Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
DrugsBelinostat·Pralatrexate·Soquelitinib
Corvus Pharmaceuticals, Inc.
Phase 3
150
Darlinghurst, Kogarah, South Brisbane, Adelaide, Bedford Park, Hobart, Box Hill, Heidelberg
2024-10-02
Active, closed
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394Dravet Syndrome
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
96
Randwick, Westmead, Brisbane, Heidelberg, Melbourne, Parkville
2024-09-25
Active, closed
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
NCT06550895Multiple Myeloma
DrugsCilta-cel·Talquetamab
Janssen Research & Development, LLC
Phase 2
11
Camperdown, Heidelberg, Melbourne
2024-09-16
Active, closed
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
NCT06537310Cancer-Neoplasms
Hoffmann-La Roche
Phase 1
34
Darlinghurst, Heidelberg
2024-09-16
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin
Bayer
Phase 3
555
Blacktown, Concord, Waratah, Buderim, Toowoomba, Heidelberg
2024-08-28
Recruiting
Silexan in the Treatment Of Posttraumatic Stress Disorder Trial
NCT06412757Post Traumatic Stress Disorder
Deakin University
Phase 3
278
Carlton, Geelong, Heidelberg, Melbourne
2024-08-26
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
DrugsSurovatamig·R-Chop
AstraZeneca
Phase 3
1,018
Clayton, Darlinghurst, Garran, Heidelberg, Macquarie University, Nedlands
2024-08-07
Recruiting
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
DrugVedolizumab
Alimentiv Inc.
Phase 4
304
Concord, South Brisbane, Adelaide, Woodville, Epping, Heidelberg, Melbourne, Murdoch
2024-08-07
By invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463Focal Epilepsy
DrugOpakalim
Biohaven Therapeutics Ltd.
Phase 2
660
Camperdown, Randwick, Herston, Fitzroy, Heidelberg, Melbourne, Parkville, Bedford Park
2024-07-30
Recruiting
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06083207Multiple Myeloma
DrugIBI3003
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
116
Wollongong, Heidelberg, Melbourne
2024-07-29
Recruiting
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
NCT06520345Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Docetaxel
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
520
Sydney, Wollongong, Melbourne, Perth, Brisbane, East Maitland, Heidelberg, Malvern
2024-07-26
Active, closed
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003Severe Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
446
Blacktown, Concord, Merewether, Box Hill, Clayton, Heidelberg, Crawley
2024-07-22
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naรฏve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649Metastatic Colorectal Cancer
DrugsBevacizumab-awwb·Lumakras·Mvasi·Sotorasib
Amgen
Phase 3
450
Camperdown, Toowoomba, Woolloongabba, Bedford Park, Woodville South, Heidelberg
2024-07-17
Active, closed
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346Essential Thrombocythemia
DrugsBomedemstat·Hydroxyurea
Merck Sharp & Dohme LLC
Phase 3
300
Westmead, Adelaide, Clayton, Heidelberg, Perth
2024-07-16
Recruiting
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT07491172Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder
CRISPR Therapeutics AG
Phase 1
90
Adelaide, Brisbane, Camperdown, Heidelberg, Melbourne
2024-06-21
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone
Celgene
Phase 3
850
Gosford, Sydney, Westmead, Tiwi, Birtinya, Southport, Frankston, Heidelberg
2024-06-19
Active, closed
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
DrugsTemodar·Niraparib·Temozolomide
Ivy Brain Tumor Center
Phase 3
450
Fitzroy, Heidelberg, Melbourne
2024-06-19
Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273Large B-cell Lymphoma
DrugsFludara·Cytoxan·Fludarabine·Cyclophosphamide
Allogene Therapeutics
Phase 2
250
Auchenflower, Hobart, Clayton, Fitzroy, Heidelberg, Nedlands
2024-06-18
Recruiting
Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients
NCT06324604Healthy Volunteers, Type 1 Diabetes
Mozart Therapeutics Australia Pty Ltd
Phase 1
96
Heidelberg, Melbourne, Fitzroy
2024-06-13
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314Advanced Melanoma
DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab
Immunocore Ltd
Phase 3
680
Waratah, Greenslopes, Nedlands, Heidelberg, North Melbourne, Wollstonecraft, Woolloongabba
2024-06-05
Active, closed
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel
Amgen
Phase 1
120
Camperdown, St Leonards, Woodville South, Heidelberg, Melbourne, St Albans
2024-05-29
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Adelaide, Fitzroy, Greenslopes, Heidelberg, Herston, Murdoch, Perth, South Brisbane
2024-05-24
Active, closed
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
NCT06393712Cerebral Amyloid Angiopathy
DrugsMivelsiran·Aln-App
Alnylam Pharmaceuticals
Phase 2
210
Adelaide, Brisbane, Heidelberg, Nedlands, Parkville
2024-05-17
Active, closed
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Focal Epilepsy
DrugOpakalim
Biohaven Therapeutics Ltd.
Phase 2/3
390
Camperdown, Randwick, Herston, Fitzroy, Heidelberg, Melbourne, Parkville, Bedford Park
2024-05-13
Active, closed
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
DrugNerandomilast
Boehringer Ingelheim
Phase 3
1,666
Garran, Camperdown, Westmead, Chermside, Adelaide, Heidelberg, Melbourne, Murdoch
2024-05-06
Active, closed
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes
Endogenex, Inc.
Not applicable
350
Camperdown, Double Bay, Saint Leonards, Box Hill, Fitzroy, Heidelberg, Melbourne
2024-05-01
Active, closed
Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation
NCT05899985Gastric Cancer, Esophageal Cancer
Ferronova Pty Ltd
Not applicable
60
Adelaide, Bedford Park, Heidelberg, Melbourne
2024-03-21
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Brisbane, Herston, South Brisbane, Adelaide, Bedford Park, Clayton, Heidelberg, Perth
2024-03-13
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
MacroGenics
Phase 1
250
Auchenflower, Kurralta Park, Heidelberg
2024-03-06
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Heidelberg, Kurralta Park
2024-03-05
Active, closed
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
NCT06230224B-Cell Non-Hodgkin Lymphoma (B-NHL)
DrugsOdronextamab·Ifosfamide·Paraplatin·Cytarabine
Regeneron Pharmaceuticals
Phase 3
216
Woolloongabba, Heidelberg
2024-02-15
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin
Boehringer Ingelheim
Phase 3
428
Randwick, St Leonards, Woolloongabba, Heidelberg, Subiaco
2024-02-09
Active, closed
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
NCT06157541Glioblastoma Multiforme, Astrocytoma, Grade IV
DrugsKeytruda·Pembrolizumab
Queensland Institute of Medical Research
Phase 1/2
58
Bowen Hills, Herston, Woolloongabba, Heidelberg
2024-02-08
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Garran, Heidelberg, Melbourne, Murdoch
2023-12-20
Active, closed
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naรฏve Mantle Cell Lymphoma
NCT05951959Mantle Cell Lymphoma (MCL)
DrugsAcalabrutinib·Venetoclax·Rituximab
AstraZeneca
Phase 2
108
Heidelberg, Kogarah, Nedlands, Sydney
2023-12-13
Active, closed
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
NCT06139406Lymphoma, Non-Hodgkin
DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543
Janssen Research & Development, LLC
Phase 1
70
Heidelberg, Melbourne, Nedlands, Randwick
2023-12-06
Recruiting
Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)
NCT06181994Chronic Subdural Hematoma
Montefiore Medical Center
Observational
5,000
Heidelberg
2023-12-05
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Blacktown, Bowral, Concord, North Ryde, Douglas, Adelaide, Heidelberg, Melbourne
2023-12-01
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDatopotamab deruxtecan·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
Camperdown, Darlinghurst, Heidelberg, Melbourne, Nedlands, Waratah
2023-11-23
Active, closed
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571NASH/MASH, NAFLD/MASLD
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
700
Broadmeadow, Westmead, Adelaide, Clayton, Epping, Heidelberg, Melbourne, Murdoch
2023-11-10
Recruiting
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
NCT06084481Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma
DrugsTelisotuzumab Adizutecan·Itraconazole·Bevacizumab
AbbVie
Phase 1
325
Camperdown, Heidelberg
2023-11-09
Active, closed
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1
21
Camperdown, Clayton, Heidelberg, Herston, Westmead
2023-11-06
Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease
DrugTreprostinil
United Therapeutics
Phase 3
698
Camperdown, Kogarah, Brisbane, Chermside, Box Hill, Clayton, Heidelberg, Midland
2023-10-30
Recruiting
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
NCT05658497Multiple Sclerosis
DrugsDiroximel Fumarate·Natalizumab·Avonex·Dimethyl Fumarate
Biogen
Observational
908
Heidelberg
2023-10-27
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
895
Clayton, Fitzroy, Heidelberg, South Brisbane, Sydney
2023-10-24
Active, closed
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
NCT05949684Myelodysplastic Syndromes
DrugsEpoetin Alfa·Reblozyl·Luspatercept
Bristol-Myers Squibb
Phase 3
402
Blacktown, Camperdown, Coffs Harbour, Gold Coast, Clayton, Heidelberg
2023-10-24
Recruiting
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
NCT06050707Anal Squamous Cell Carcinoma
University Health Network, Toronto
Phase 2
80
Heidelberg
2023-09-29
Recruiting
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
NCT05722938Community-acquired Pneumonia
Biotest
Phase 3
590
Woolloongabba, Clayton, Footscray, Heidelberg, Saint Albans, Nedlands
2023-09-09
Active, closed
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
NCT05788081Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IV
DrugsGolcadomide·Opdivo·Rituximab·Nivolumab
Olivia Newton-John Cancer Research Institute
Phase 2
40
Ballarat, Box Hill, Geelong, Heidelberg, Perth
2023-08-31
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
DrugsCapeox·Dostarlimab·Folfox
GlaxoSmithKline
Phase 3
892
Newcastle, St Leonards, Woolangabba, Heidelberg, Melbourne
2023-08-01
Active, closed
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
NCT05845814Metastatic Urothelial Carcinoma, Urothelial Neoplasms
DrugsPembrolizumab/Vibostolimab·Pembrolizumab/Favezelimab·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
390
Brisbane, Heidelberg
2023-06-23
Active, closed
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
DrugFurmonertinib
ArriVent BioPharma, Inc.
Phase 3
398
Heidelberg, Blacktown, St Leonards, Woolloongabba
2023-06-01
Recruiting
EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)
NCT06923761Advanced Solid Malignancy
Grey Wolf Therapeutics
Phase 1/2
300
Adelaide, Bedford Park, Blacktown, Darlinghurst, Heidelberg, Melbourne, South Brisbane, Wollongong
2023-05-21
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
NCT05800665Advanced Prostate Cancer, Metastatic Prostate Cancer
Genentech, Inc.
Phase 1
210
Darlinghurst, New South Wales, Clayton, Heidelberg
2023-05-02
Recruiting
Platform of Randomized Adaptive Clinical Trials in Critical Illness
NCT05440851Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
University Health Network, Toronto
Not applicable
6,250
Camperdown, Kingswood, Wollongong, Bedford Park, Darlinghurst, Bendigo, Geelong, Heidelberg
2023-04-30
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Randwick, Camperdown, Fitzroy, Heidelberg, Kogarah, Melbourne, Parkville, South Brisbane
2023-04-25
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guรฉrin (BCG) in Participants With BCG-naรฏve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 3
1,135
Heidelberg, Macquarie University, Nedlands, South Brisbane
2023-03-23
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Adelaide, Box Hill, Campbelltown, Camperdown, Clayton, Fitzroy, Heidelberg, Herston
2023-02-15
Recruiting
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142Primary Generalized Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
160
Kogarah, South Brisbane, Melbourne, Heidelberg, Parkville
2023-02-14
Active, closed
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone
Genmab
Phase 3
900
Liverpool, Adelaide, Clayton, Heidelberg, Melbourne, Nedlands, Perth
2023-02-08
Recruiting
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
NCT05518578Epilepsy, Seizures, Epileptic
DrugSPN-817
Supernus Pharmaceuticals, Inc.
Phase 2
60
Randwick, Sydney, Brisbane, Box Hill, Heidelberg, Melbourne, Parkville
2023-02-07
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562H3 K27M, Glioma
DrugDordaviprone
Jazz Pharmaceuticals
Phase 3
510
Randwick, Sydney, Herston, Hobart, Heidelberg, Nedlands
2023-01-23
Recruiting
Alleviant ALLAY-HF Study
NCT05685303Heart Failure
Alleviant Medical, Inc.
Not applicable
700
Clayton, Heidelberg
2023-01-10
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984Advanced Solid Tumors
DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin
AbbVie
Phase 1
288
Camperdown, Darlinghurst, Heidelberg, Melbourne
2022-12-05
Recruiting
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
NCT05678621Haematological Malignancy, Hypogammaglobulinemia
DrugsImmunoglobulins·Trimethoprim-sulfamethoxazole
Monash University
Phase 2/3
300
Garran, Concord, St Leonards, Clayton, Heidelberg, Melbourne, St Albans
2022-11-30
Active, closed
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma
DrugTYRA-300
Tyra Biosciences, Inc
Phase 1/2
310
Macquarie Park, Southport, Woolloongabba, Heidelberg, Melbourne, Nedlands
2022-11-22
Recruiting
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
NCT05180097Hodgkin Lymphoma
DrugsBrentuximab Vedotin·Dexamethasone·Gemcitabine·Cisplatin
Canadian Cancer Trials Group
Phase 2
84
Concord, Nowra, Wollongong, Adelaide, Heidelberg, Perth
2022-11-01
Active, closed
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
NCT05483868Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms
DrugBel-sar
Aura Biosciences
Phase 1
55
Westmead, Heidelberg, Langwarrin, Parkville, Nedlands
2022-09-26
Active, closed
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
DrugElironrasib
Revolution Medicines, Inc.
Phase 1
222
Sydney, Frankston, Heidelberg, Warrnambool
2022-09-19
Active, closed
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940Colorectal Cancer
DrugsZanzalintinib·Regorafenib·Atezolizumab
Exelixis
Phase 3
901
Albury, Bankstown, Bedford Park, Heidelberg, Melbourne, Port Macquarie, Woodville South
2022-09-07
Active, closed
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
NCT05494606Ulcerative Colitis
AbbVie
Observational
785
Blacktown, Kingswood, North Mackay, Heidelberg, Parkville
2022-08-15
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
DrugsAbraxane·Nab-paclitaxel·Gemcitabine
Panbela Therapeutics, Inc.
Phase 2/3
600
Garran, Tweed Heads, Kurralta Park, Heidelberg, Murdoch
2022-08-08
Active, closed
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT05217446Metastatic Colorectal Cancer
DrugsEncorafenib·Erbitux·Cetuximab·Keytruda
Pfizer
Phase 2
108
Heidelberg, Melbourne, Parkville
2022-07-11
Active, closed
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
NCT05364073Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations
DrugFurmonertinib
ArriVent BioPharma, Inc.
Phase 1
160
Blacktown, St Leonards, Heidelberg
2022-06-30
Active, closed
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
NCT05367440Metastatic Prostate Cancer
DrugsSaruparib·Zytiga·Xtandi·Apalutamide
AstraZeneca
Phase 1/2
174
Camperdown, Darlinghurst, East Melbourne, Heidelberg, Melbourne, St Leonards
2022-06-02
Active, closed
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
NCT05308654Relapsed/Refractory Multiple Myeloma
DrugsABBV-453·Daratumumab·Lenalidomide·Dexamethasone
AbbVie
Phase 1
34
Liverpool, Fitzroy, Fitzroy Melbourne, Heidelberg, Richmond
2022-05-17
Active, closed
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
NCT05270044Melanoma
Pierre Fabre Medicament
Phase 3
815
Sydney, Wollstonecraft, Woolloongabba, North Adelaide, Box Hill, Heidelberg, Prahran, Nedlands
2022-05-02
Recruiting
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
NCT05219617Seizures, Lennox Gastaut Syndrome
SK Life Science, Inc.
Phase 3
252
Heidelberg, Melbourne, Nedlands, South Brisbane
2022-04-28
Recruiting
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rฮฑ Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
DrugsAvelumab·Aldesleukin·Nivolumab
Aulos Bioscience, Inc.
Phase 1/2
159
Miranda, Bedford Park, Clayton, Frankston, Heidelberg, Melbourne, Saint Albans
2022-04-04
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
DrugsTelisotuzumab vedotin·Docetaxel
AbbVie
Phase 3
768
Port Macquarie, Westmead, Geelong, Heidelberg
2022-03-25
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
DrugsBelzutifan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,800
Blacktown, Macquarie University, North Tamworth, Brisbane, Elizabeth Vale, Heidelberg, Murdoch
2022-03-15
Active, closed
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582HER2 Positive Breast Cancer
DrugsPerjeta·Tucatinib·Herceptin·Pertuzumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Camperdown, Macquarie University, Westmead, Adelaide, Bedford Park, Box Hill, Heidelberg, Subiaco
2022-03-07
Active, closed
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340Metastatic Non Small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
740
Heidelberg, Mount Waverley, Camperdown, Woodville South
2022-03-04
Active, closed
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509Atherosclerotic Cardiovascular Disease
DrugObicetrapib
NewAmsterdam Pharma
Phase 3
9,541
Adelaide, Bedford Park, Campbelltown, Chermside, Clayton, Halls Creek, Heidelberg, Melbourne
2022-02-07
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
DrugsMonalizumab·Oleclumab·Durvalumab
AstraZeneca
Phase 3
1,051
Box Hill, East Melbourne, Elizabeth Vale, Gosford, Heidelberg, Kogarah, South Brisbane, St Albans
2022-02-07
Recruiting
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation
NCT04455932Hepatocellular Carcinoma, HCC
Concord Repatriation General Hospital
Not applicable
476
Camperdown, Concord, Gosford, Randwick, Westmead, Brisbane, Fitzroy, Heidelberg
2022-01
Active, closed
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil
Jazz Pharmaceuticals
Phase 3
920
Bedford Park, Heidelberg, Liverpool, Murdoch
2021-12-02
Active, closed
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
NCT04958239Neoplasms
DrugsEzabenlimab·Pembrolizumab
Boehringer Ingelheim
Phase 1
151
Albury, Darlinghurst, Douglas, Heidelberg
2021-10-18
Active, closed
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab
AbbVie
Phase 1
520
South Brisbane, Heidelberg
2021-10-13
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
645
Concord, Waratah, Woolloongabba, Fitzroy, Heidelberg, Melbourne, Nedlands, West Perth
2021-09-13
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
Concord, Liverpool, Penrith, Greenslopes, Herston, Box Hill, Clayton, Heidelberg
2021-08-19
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine
Janssen Research & Development, LLC
Phase 3
743
Camperdown, Fitzroy, Heidelberg, Herston, Melbourne, Murdoch, Waratah, Westmead
2021-08-19
Active, closed
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
NCT04962126Follicular Lymphoma
DrugsTecentriq·Obinutuzumab·Atezolizumab
Olivia Newton-John Cancer Research Institute
Phase 2
15
Ballarat, Box Hill, Heidelberg
2021-08-17
Active, closed
The Cryopreserved vs. Liquid Platelets Trial
NCT03991481Surgical Blood Loss, Hemorrhage
Australian and New Zealand Intensive Care Research Centre
Phase 3
388
Sydney, Brisbane, Douglas, Southport, Fitzroy, Heidelberg
2021-08-17
Active, closed
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04974398Nasopharyngeal Carcinoma
DrugPenpulimab
Akeso
Phase 3
296
Camperdown, Darlinghurst, St Leonards, Heidelberg, Nedlands
2021-08-16
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Pierre Fabre Medicament
Phase 1
400
Waratah, Wollstonecraft, Southport, Heidelberg, Perth
2021-08-04
Active, closed
PMCF Study in Patients With Acute or Chronic Aortic Dissection or Aortic Aneurysm Treated With E-vita OPEN NEO
NCT04986709Aortic Dissection, Aortic Aneurysm
JOTEC GmbH
Observational
114
Heidelberg
2021-08-01
Recruiting
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
European Foundation for Study of Chronic Liver Failure
Observational
3,000
Heidelberg, Nedlands, Sydney
2021-07-08
Active, closed
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer
DrugsAdagrasib·Erbitux·MFOLFOX6·Folfiri
Mirati Therapeutics Inc.
Phase 3
461
Bedford Park, Clayton, Garran, Heidelberg, Melbourne, Waratah
2021-06-24
Active, closed
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
NCT04739761Breast Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 3
506
Adelaide, Auchenflower, Clayton, Heidelberg, St Leonards, Subiaco
2021-06-22
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
DrugsPosaconazole·Sonrotoclax·Azacitidine
BeOne Medicines
Phase 1/2
260
Concord, Kogarah, Orange, Southport, Clayton, Fitzroy, Heidelberg, Melbourne
2021-05-24
Active, closed
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
NCT04817007Myelofibrosis
DrugsBMS-986158·Fedratinib·Ruxolitinib
Bristol-Myers Squibb
Phase 1/2
216
Blacktown, Wollongong, East Melbourne, Heidelberg, Nedlands, West Perth
2021-03-22
Recruiting
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Durvalumab
AstraZeneca
Phase 1
304
Adelaide, Heidelberg, Nedlands
2021-03-09
Active, closed
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT04594642B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
DrugSurovatamig
AstraZeneca
Phase 1
226
Heidelberg, Hobart, Melbourne
2021-03-02
Active, closed
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
NCT04721015Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
DrugsOsimertinib·Docetaxel
AbbVie
Phase 1
81
Wollongong, Heidelberg
2021-02-23
Active, closed
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia
DrugBlinatumomab
Amgen
Phase 1/2
181
Randwick, Westmead, South Brisbane, Adelaide, Clayton, Heidelberg, Melbourne, Nedlands
2021-01-04
Active, closed
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421Neoplasms
DrugsEncorafenib·Leucovorin·Irinotecan·Adrucil
Pfizer
Phase 3
841
Camperdown, Liverpool, St Leonards, Herston, Woolloongabba, Adelaide, Clayton, Heidelberg
2020-12-21
Active, closed
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652Non-small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Docetaxel
Daiichi Sankyo
Phase 3
605
Bedford Park, Blacktown, Heidelberg, North Ryde, Sydney, Wollongong
2020-12-21
Active, closed
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naรฏve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204Small Cell Lung Cancer
DrugsOlaparib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
672
Campbelltown, Kingswood, Waratah, Southport, Frankston, Heidelberg, St Albans
2020-12-08
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
DrugsTrastuzumab emtansine·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 3
1,600
Adelaide, Camperdown, Clayton, Heidelberg, Melbourne, Nedlands, Saint Leonards, Subiaco
2020-12-04
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436Multiple Sclerosis
DrugsOcrelizumab·Methylprednisolone
Hoffmann-La Roche
Phase 3
864
Heidelberg
2020-11-26
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
DrugsSaruparib·Camizestrant·Datopotamab deruxtecan·Trastuzumab deruxtecan
AstraZeneca
Phase 1/2
702
Heidelberg, Melbourne
2020-11-12
Active, closed
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT04663347Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
DrugsR-Ice·Rituximab and lenalidomide·Gemcitabine and oxaliplatin·Epcoritamab
Genmab
Phase 1/2
543
Heidelberg, Nedlands
2020-11-03
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449Multiple Sclerosis, Primary Progressive
DrugsFenebrutinib·Ocrelizumab
Hoffmann-La Roche
Phase 3
985
Camperdown, Liverpool, New Lambton, Woolloongabba, Box Hill, Heidelberg, Parkville
2020-10-26
Active, closed
Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)
NCT03868618Obstructive Sleep Apnea
Nyxoah S.A.
Not applicable
115
Wollongong, Heidelberg, Nedlands
2020-10-14
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone
Acerta Pharma BV
Phase 3
611
Camperdown, Darlinghurst, Heidelberg, Hobart, Kogarah, Nedlands, Westmead
2020-10-08
Active, closed
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963Squamous Cell Carcinoma of the Head and Neck
DrugsMonalizumab·Cetuximab
AstraZeneca
Phase 3
370
Camperdown, Elizabeth Vale, Heidelberg, Melbourne
2020-10-02
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Osimertinib
Janssen Research & Development, LLC
Phase 3
1,074
Bedford Park, Heidelberg, Malvern, Murdoch, Nedlands, Westmead, Wollongong, Woolloongabba
2020-09-30
Active, closed
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748Myelodysplastic Syndrome (MDS)
DrugsVenclexta·Azacitidine·Venetoclax
AbbVie
Phase 3
531
Blacktown, Kogarah, Port Macquarie, Southport, Adelaide, Fitzroy Melbourne, Heidelberg
2020-09-10
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
Auchenflower, Blacktown, Camperdown, Heidelberg, Melbourne, Nedlands
2020-08-18
Recruiting
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung
DrugPembrolizumab
Bicara Therapeutics
Phase 1
292
Camperdown, Waratah, Heidelberg, Melbourne
2020-06-01
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
NCT04241185Urinary Bladder Neoplasms
DrugsMitomycin C·Fluorouracil·Adrucil·Keytruda
Merck Sharp & Dohme LLC
Phase 3
520
Liverpool, St Leonards, Clayton, Heidelberg, Nedlands
2020-05-19
Active, closed
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
NCT04223856Urothelial Cancer
DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin
Astellas Pharma Global Development, Inc.
Phase 3
886
Box Hill, Douglas, Heidelberg, Macquarie Park, South Australia, South Brisbane
2020-03-30
Recruiting
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
NCT04310930Pulmonary Disease Due to Mycobacteria (Diagnosis)
DrugsImipenem·Tigecycline·Amikacin·Clofazimine
The University of Queensland
Phase 2/3
300
Kogarah, South Brisbane, Woolloongabba, Heidelberg, Parkville, Perth, Adelaide, Birtinya
2020-03-02
Active, closed
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105B-cell Non-Hodgkin Lymphoma (B-NHL)
DrugOdronextamab
Regeneron Pharmaceuticals
Phase 2
515
East Albury, Tweed Heads, East Melbourne, Frankston, Geelong, Heidelberg, Perth
2019-11-13
Active, closed
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879Carcinoma, Non-Small-Cell Lung
DrugsOpdivo·Pemetrexed·Docetaxel·Nivolumab
Bristol-Myers Squibb
Phase 3
461
Sydney, Heidelberg, Melbourne, North Ballarat
2019-11-05
Active, closed
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647HER2-positive Breast Cancer
DrugsTucatinib·Trastuzumab emtansine
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
North Sydney, Westmead, Heidelberg, Melbourne, Parkville, Nedlands
2019-10-02
Active, closed
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
NCT04083339Diabetic Cardiomyopathies
Applied Therapeutics, Inc.
Phase 3
675
Chermside, Milton, Taringa, Hobart, Geelong, Heidelberg, Melbourne
2019-09-20
Active, closed
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
NCT04068610Metastatic Microsatellite-stable Colorectal Cancer
DrugsOleclumab·Folfox·Durvalumab·Bevacizumab
MedImmune LLC
Phase 1/2
61
Clayton, Heidelberg, Melbourne
2019-09-13
Active, closed
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232Ulcerative Colitis
DrugEtrasimod
Pfizer
Phase 3
896
Liverpool, Birtinya, Bowen Hills, Buderim, Mackay, Maroochydore, North Mackey, Heidelberg
2019-09-05
Active, closed
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
NCT04035005Multiple Sclerosis, Primary Progressive
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
1,013
Camperdown, Heidelberg, Parkville
2019-08-12
Active, closed
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030Metastatic Colorectal Cancer
DrugsLeucovorin·Fluorouracil·Ipilimumab·Irinotecan
Bristol-Myers Squibb
Phase 3
839
Westmead, Woolloongabba, Elizabeth Vale, Clayton, Heidelberg
2019-08-05
Recruiting
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT03970447Glioblastoma
DrugsAZD1390·Troriluzole·Paxalisib·CCNU
Global Coalition for Adaptive Research
Phase 2/3
2,250
St Leonards, Waratah, Herston, Bedford Park, Heidelberg, Melbourne
2019-07-30
Active, closed
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022Non-Small Cell Lung Cancer
DrugSunvozertinib
Dizal Pharmaceuticals
Phase 1/2
315
Blacktown, Camperdown, Heidelberg, Kogarah, North Melbourne, Perth, Wollongong
2019-07-09
Active, closed
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486Non-Small Cell Lung Cancer
DrugsPemetrexed/Cisplatin·Pemetrexed/Carboplatin·Osimertinib
AstraZeneca
Phase 3
587
Camperdown, Chermside, Elizabeth Vale, Heidelberg, Kogarah, Melbourne
2019-07-02
Active, closed
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244Prostatic Neoplasms
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
2,517
Box Hill, Darlinghurst, Heidelberg, Malvern, Parkville, St Leonards, Wahroonga, Westmead
2019-06-11
Recruiting
Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction
NCT05651347Fetal Growth Retardation, Stillbirth and Fetal Death, Pregnancy Preterm
DrugMelatonin
Monash University
Phase 3
336
Camperdown, Newcastle, South Brisbane, Southport, North Adelaide, Clayton, Heidelberg, Parkville
2019-05-29
Recruiting
Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk
NCT04029363Mitral Regurgitation
HighLife SAS
Not applicable
120
Darlinghurst, Newcastle, Sydney, Auchenflower, Adelaide, Brisbane, Heidelberg, Melbourne
2019-05-28
Active, closed
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
DrugsZanzalintinib·Avelumab·Tecentriq·Atezolizumab
Exelixis
Phase 1
325
Darlinghurst, Liverpool, South Brisbane, Kurralta Park, Heidelberg
2019-03-20
Active, closed
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261Chronic Lymphocytic Leukemia
DrugsVenclyxto·Acalabrutinib·Venclexta·Obinutuzumab
Acerta Pharma BV
Phase 3
984
Adelaide, Darlinghurst, Heidelberg, Kogarah, Melbourne, Nedlands, Waratah, Woolloongabba
2019-02-25
Recruiting
Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
NCT05685745Infant, Extremely Premature, Obstetric Labor, Premature, Premature Birth, Intensive Care, Neonatal
The University of Texas Health Science Center, Houston
Observational
5,000
South Brisbane, Heidelberg, Parkville, Perth
2019-01-01
Active, closed
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03611868Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation
DrugPembrolizumab
Ascentage Pharma Group Inc.
Phase 1/2
230
Brisbane, South Brisbane, Bedford Park, Heidelberg
2018-08-29
Active, closed
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
NCT03383458Hepatocellular Carcinoma, Liver Cancer
DrugsOpdivo·Nivolumab
Bristol-Myers Squibb
Phase 3
545
Blacktown, Camperdown, Concord, Herston, Adelaide, Heidelberg, Nedlands
2018-04-18
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab
Janssen Research & Development, LLC
Phase 2/3
1,409
Adelaide, Clayton, Concord, Heidelberg, Nedlands, North Terrace, Parkville, Penrith
2018-04-13
Active, closed
The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants
NCT03667651Eczema, Asthma, Allergy;Food
University of Melbourne
Phase 3
760
Heidelberg, Parkville
2018-03-06
Active, closed
Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A
NCT03245021Follicular Lymphoma
DrugsOpdivo·Rituximab
Dr. Eliza Hawkes
Phase 1
39
Ballarat, Box Hill, Clayton, Heidelberg, Melbourne
2017-09-07
Active, closed
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT02972840Lymphoma, Mantle Cell
DrugsAcalabrutinib·Bendamustine·Rituximab
Acerta Pharma BV
Phase 3
635
Bedford Park, Concord, Frankston, Gosford, Heidelberg, Herston, Kogarah, Murdoch
2017-04-05
Active, closed
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
NCT03036098Urothelial Cancer
DrugsYervoy·Opdivo·Ipilimumab·Nivolumab
Bristol-Myers Squibb
Phase 3
1,314
Waratah, Westmead, South Brisbane, Tugun, Heidelberg, Doubleview
2017-03-24
Active, closed
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
NCT02988960Advanced Solid Tumors Cancer
DrugsABBV-927·Budigalimab
AbbVie
Phase 1
163
Frankston, Heidelberg
2017-02-22
Active, closed
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
NCT03049189Neuroendocrine Tumors
Drugs177Lu-DOTATOC·Everolimus
ITM Solucin GmbH
Phase 3
324
Saint Leonards, Heidelberg, Melbourne, Murdoch
2017-02-02
Active, closed
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861Renal Cell Carcinoma
DrugsSunitinib·Everolimus·Lenvatinib·Pembrolizumab
Eisai Inc.
Phase 3
1,069
Box Hill, Heidelberg, Hobart, Macquarie Park, South Brisbane, St Albans
2016-10-13
Active, closed
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
NCT02609776Non-Small-Cell Lung Cancer
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 1
751
Camperdown, Heidelberg, Kogarah, Murdoch, Woolloongabba
2016-05-24
Active, closed
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
DrugsRamucirumab·Gemcitabine·Cisplatin
Eli Lilly and Company
Phase 2
309
Waratah, Adelaide, Heidelberg
2016-05-19
Active, closed
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
DrugEntrectinib
Hoffmann-La Roche
Phase 2
534
Liverpool, Newcastle, Bedford Park, Heidelberg
2015-11-19
Active, closed
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma
DrugOsimertinib
AstraZeneca
Phase 3
682
Bedford Park, Camperdown, Darlinghurst, Heidelberg, Kogarah, Kurralta Park, Woolloongabba
2015-10-21
Active, closed
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
NCT02393625ALK-positive NSCLC
DrugsCeritinib·Nivolumab
Novartis Pharmaceuticals
Phase 1
57
Heidelberg
2015-05-27
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
700
Adelaide, Coburg, Concord, Heidelberg, Melbourne, Perth, Prahran, Wahroonga
2013-09-09
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Heidelberg, Parkville, Randwick
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Heidelberg, Parkville, Randwick
2013-08-26
Active, closed
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
NCT01843374Unresectable Pleural or Peritoneal Malignant Mesothelioma
DrugTremelimumab
MedImmune LLC
Phase 2
571
Adelaide, Auchenflower, Box Hill, Chermside, East Bentleigh, Gosford, Heidelberg, Nedlands
2013-05-17
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Westmead, Cairns, Herston, Woolloongabba, Adelaide, Heidelberg, Parkville, Murdoch
2013-03-18
Active, closed
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
NCT00626990Brain and Central Nervous System Tumors
DrugsTemodal·Temodar·Temozolomide
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
751
St Leonards, Sydney, Brisbane, Parkville, Bedford Park, Heidelberg, Hobart, Melbourne
2007-12
Rows per page Showing 1–263 of 263
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-australia/city/heidelberg

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,335 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 263 of those studies with a site in Heidelberg.

How many clinical trials are recruiting in Heidelberg?

134 of the 263 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 8 have not yet opened recruitment, 118 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Heidelberg), 263 studies
PhaseStudiesRecruitingShare
Phase 31255747.5%
Phase 2371914.1%
Phase 1361413.7%
Phase 1/2301911.4%
Not applicable1284.6%
Observational1284.6%
Phase 2/31083.8%
Phase 4110.4%

Most active sponsors

Lead sponsors with the most studies (Heidelberg)
Lead sponsorStudiesRecruiting
AstraZeneca2714
Janssen Research & Development, LLC166
AbbVie124
Hoffmann-La Roche115
Bristol-Myers Squibb104
Boehringer Ingelheim85
BeOne Medicines77
Eli Lilly and Company53
Merck Sharp & Dohme LLC50
Amgen41
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.